News | Women's Health | June 29, 2015

UCLA study finds partial breast irradiation produces similar results to whole breast irradiation, with treatment reduced to one week

UCLA, breast cancer, partial breast irradiation, Mitchell Kamrava

June 29, 2015 - Women diagnosed with breast cancer and treated with one week of partial breast radiation after surgical tumor removal saw no increase in cancer recurrence or difference in cosmetic outcomes, according to a new UCLA study. Subjects were compared to women who received radiation of the entire breast for a period of up to six weeks after surgery. The study is one of the largest ever done on partial breast irradiation.

The study lasted two decades and was led by Mitchell Kamrava, M.D., an assistant professor of radiation oncology at UCLA and member of the Jonsson Comprehensive Cancer Center. Kamrava and his team found that with partial breast irradiation, the total length of treatment can be reduced to a week because the smaller area of treatment allows for a higher dosage per treatment. Additionally, because partial breast radiation is more targeted, there is less exposure to vital organs like the lungs and the heart.

The new treatment, formally known as accelerated partial breast irradiation with interstitial multicatheter brachytherapy, works by radiating only breast tissue in and around the area where the tumor was removed. The current standard of care, called whole breast conservation therapy, involves irradiating the entire breast after surgery, usually over the course of five to seven weeks. This results in prolonged exposure to radiation and can potentially lead to more side effects.

"This gives us confidence there is a group of women who are suitable candidates for partial breast radiation and more women should discuss this treatment option with their doctors," said Kamrava.

The study followed more than 1,000 women who received partial breast irradiation after surgery, with an average follow-up of about seven years.

The next phase for Kamrava and his team will be to analyze the results of randomized trials comparing whole breast versus partial breast irradiation.

For more information: www.cancer.ucla.edu


Related Content

News | Breast Imaging

Dec. 01, 2025 — DeepHealth, a wholly owned subsidiary of RadNet, Inc., has launched the DeepHealth Breast Suite,2 an end ...

Time December 04, 2025
arrow
News | Mammography

Nov. 30, 2025 — At RSNA 2025, Siemens Healthineers will introduce new capabilities for its Mammomat B.brilliant ...

Time December 02, 2025
arrow
News | RSNA 2025

Dec. 2, 2025 — Lunit, a provider of AI for cancer diagnostics and precision oncology, will present 14 studies at RSNA ...

Time December 02, 2025
arrow
News | Mammography

Nov. 26, 2025 — GE HealthCare has announced it received FDA Premarket Authorization for Pristina Recon DL, an advanced ...

Time November 29, 2025
arrow
News | Ultrasound Imaging

Nov. 12, 2025 — GE HealthCare and DeepHealth, Inc., a wholly owned subsidiary of RadNet, Inc., have announced their ...

Time November 20, 2025
arrow
News | Breast Imaging

Nov. 17, 2025 — RadNet, Inc. and its wholly owned subsidiary, DeepHealth have announced results from the largest real ...

Time November 17, 2025
arrow
News | Radiology Business

Nov. 12, 2025 — Siemens has announced plans to deconsolidate its remaining stake in Siemens Healthineers (currently ...

Time November 13, 2025
arrow
News | Artificial Intelligence

Nov. 6, 2025 — Lunit, a provider of AI for cancer diagnostics and precision oncology, recently announced that Volpara ...

Time November 07, 2025
arrow
News | RSNA 2025

Nov. 3, 2025 — QT Imaging Holdings has announced that its chief medical officer, Elaine luanow, MD, will host a seminar ...

Time November 04, 2025
arrow
News | Women's Health

Nov. 3, 2025 — —A new radioimmunotherapy approach has the potential to cure human epidermal growth factor receptor 2 ...

Time November 04, 2025
arrow
Subscribe Now